Judge Dismisses Lanham Act Claims Against GLP-1 Drug Seller, Grants Leave To Amend
NEW YORK — A New York federal judge ruled that Novo Nordisk A/S and Novo Nordisk Inc. failed to plausibly allege that a company falsely advertised compounded semaglutide products as equivalent...To view the full article, register now.
Already a subscriber? Click here to view full article